Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St Joseph's Hospital, Catholic Healthcare West, 500 W. Thomas Road, Suite 800, Phoenix, AZ 85013, USA.
Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):421-31. doi: 10.1586/erp.11.41.
Although the incidence of ovarian cancer is less than that of other female cancers, the morbidity and mortality associated with the disease course is high. Because treatment involves radical surgery and intense courses of chemotherapy, health-related quality of life (HRQOL) is often compromised. Most patients recur post-first-line therapy and undergo multiple rounds of chemotherapy. Thus, HRQOL is further disrupted. As the ongoing search for optimal therapies in both the first-line and recurrent setting continues, much attention is paid towards clinical trial design and implementation. Over the last decade, patient-reported outcomes and HRQOL measurement have become an integral part of these trials. HRQOL data are valued in examining the extent of treatment benefit and therefore can aid in decision-making during active treatment and palliative care. HRQOL and patient-reported outcome measurement is also useful in determining symptom prevalence, severity and management. This article highlights the state of the science of HRQOL measurement in clinical trial design and outcomes. In addition, symptom management in ovarian cancer and its ability to modulate quality of life will be explored.
尽管卵巢癌的发病率低于其他女性癌症，但与疾病过程相关的发病率和死亡率很高。由于治疗涉及根治性手术和强化化疗，因此健康相关生活质量（HRQOL）常常受到影响。大多数患者在一线治疗后复发，并接受多轮化疗。因此，HRQOL 进一步受到干扰。随着在一线和复发性疾病治疗中继续寻找最佳治疗方法，临床试验设计和实施受到了极大的关注。在过去十年中，患者报告的结果和 HRQOL 测量已成为这些试验的重要组成部分。在评估治疗获益程度时，HRQOL 数据很有价值，因此可以在积极治疗和姑息治疗期间帮助决策。HRQOL 和患者报告的结果测量在确定症状的普遍性、严重程度和管理方面也很有用。本文重点介绍 HRQOL 测量在临床试验设计和结果中的科学现状。此外，还将探讨卵巢癌的症状管理及其对生活质量的调节作用。
